Regulatory
Interaction Unknown
The FDA's Pharmacy Compounding Advisory Committee (PCAC) convened July 23–24, 2026 to evaluate BPC-157 and TB-500 for the 503A Bulk Drug Substances List — a regulatory gate, not an approval. Inclusion would permit licensed compounding pharmacies to prepare these peptides under individual prescriptions, but it does not alter WADA's prohibition, eliminate immunogenicity concerns, or validate any specific athlete recovery protocol.